Expiration date: 08/2025

The composition and form of issue:

Cream. 1 g contains:

hydrocortisone 17-n-butyrate 1 mg

excipients: cetostearyl alcohol tsetomakrohol liquid paraffin petroleum jelly white metilgidroksibenzoat citric acid, sodium citrate, water 

in the box to 15 grams in a cardboard bundle 1 tuba.

Ointment. 1 g contains:

hydrocortisone 17-n-butyrate 1 mg

excipients: white vaseline 

in the box to 15 grams in a cardboard bundle 1 tuba.

Lotion. 1 ml contains:

hydrocortisone 17-n-butyrate 1 mg

excipients: glycerin isopropyl alcohol PVP citric acid sodium citrate water 

in polyethylene bottles with dispenser 20 ml in a cardboard pack 1 bottle.

Feature:

Cream — a homogeneous mass of white color.

Ointment nearly colorless, translucent fatty mass.

The lotion is colorless, transparent liquid with a smell of alcohol.

Pharmacokinetics:

Suction: after application to the skin hydrocortisone easily reaches the stratum corneum of the skin. Slightly absorbed into the systemic circulation and can have systemic effects. The absorption of hydrocortisone increases with use on extensive areas of skin, when applied on the skin or in the skin folds and under the application of an occlusive bandage for a long time. The absorption of hydrocortisone from the epidermis in children is more pronounced than in adults. Can accumulate in the cells of the Horny layer of the skin.

Metabolism: biotransformiroetsa directly in the epidermis, and absorbirowawrzayasa part is in the liver. The products of metabolism of butyric acid and hydrocortisone are eliminated quickly from the body. Due to the absence of Halogens in the formula and the characteristics of the kinetics significantly reduced the risk of local and systemic side effects.

Description pharmacological action:

Glucocorticosteroids for external use. Anti-inflammatory, antiallergic, antipruritic, antiexudative effect, reduces the permeability of capillaries. Inhibits the activity of phospholipase A2 which leads to suppression of the synthesis of PG and leukotrienes. Inhibits the migration of leukocytes and lymphocytes in inflammation, inhibits the proteolytic activity of tissue kinins, restrain the growth of fibroblasts, prevent the development of connective tissue in the inflammation. Reduces symptoms of hypersensitivity reactions, proliferative and exudative processes in the connective tissue in the middle of inflammation, reduces hyperemia.

Indications:

Uninfected, sensitive to glucocorticoids, skin diseases: dermatitis (including allergic, atopic, seborrheic), atopic eczema (including contact, chronic, children's), psoriasis (including scalp), erythroderma, photo.

Contraindications:

Hypersensitivity, bacterial skin infections, fungal infections, vulgaris and acne rosacea, perioral dermatitis (dermatitis perioralis), the period after vaccination age to 2 years.

Not recommended for use during pregnancy, except in cases where therapeutic benefit to the mother outweighs risk to the fetus.

Application of pregnancy and breast-feeding:

Glucocorticoids cross the placenta. Effects on the fetus may be particularly pronounced when applying the product on large surfaces. Latikort may apply to pregnant women only in cases when the benefits exceed the risks of use. Do not use in the first trimester of pregnancy.

In the period of breast — feeding with caution (short for a surface). Not to apply to the skin of the breast.

Side effects:

Rare: possible skin irritation, systemic glucocorticoid effects (long-term use, when applied under an occlusive bandage and/or extensive damage surface of the skin).

Method of application and dose:

Externally. A small amount applied to the affected areas of skin 2-4 times a day, with the emergence of positive dynamics — 1-2 times a day, not more than 2 g/day (if necessary), duration of use not more than 2 weeks.

Chronic, licenzirovanie, hypertrophic manifestations: we recommend the use under occlusive dressings, replaced every 24 to 48 hours

Acute weeping inflammatory condition: a cream or lotion, in subacute conditions and lichenization — ointment.

The drug is used in children 6 months of age.

Before using the drug, the patient should know that:

• the drug should be used only in such manner as prescribed by a doctor
  
• the use of occlusive bandages is possible only after consultation with your doctor
  
• in case of occurrence of adverse events during treatment should consult a doctor.
  

Overdose:

May occur after prolonged use on large areas of skin, in the form of symptoms gipercortitizma. The symptoms disappear after cessation of treatment.

Special instructions:

Avoid prolonged use of the drug (prolonged use on large surface may cause symptoms of Cushing).

With the development of infection at the application site, you must assign an antibacterial treatment.

With extreme caution should be applied to the skin (may cause side effects telangiectasia, atrophy, dermatitis perioralis, even after short-term use), in the case of already existing atrophic conditions of the skin (especially in elderly persons).

During the period of drug therapy is not a vaccination.

The drug is not limiting psycho-physical abilities, abilities to control vehicles and maintenance machinery in motion.